Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights • Highlights • Key pipeline PART 05: Market landscape • Market overview • Five forces analysis PART 06: Market segmentation by type • Hypothyroidism • Hyperthyroidism PART 07: Geographical segmentation • Thyroid gland disorder treatment in Americas • Thyroid gland disorder treatment market in EMEA • Thyroid gland disorder treatment market in APAC PART 08: Market drivers • Rising global awareness programs • Increasing demand for levothyroxine • Growing patient population with iodine deficiency PART 09: Impact of drivers PART 10: Market Challenges • High entry barrier • Product recall • Side effects leading to lesser patient adherence PART 11: Impact of drivers and challenges PART 12: Market trends • Rising focus on emerging economies • Increased outsourcing of non-core activities • Growing focus on natural drugs PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Abbott • AbbVie • Allergan • Merck Sharp & Dohme • Pfizer • RLC LABS PART 15: Appendix • List of abbreviations List of Exhibits  Exhibit 01: Key pipeline products and clinical trial stage Exhibit 02: Global thyroid disorder treatment market snapshot Exhibit 03: Global thyroid gland disorder treatment market 2016-2021 ($ millions) Exhibit 04: Five forces analysis Exhibit 05: Symptoms of hypothyroidism disorder Exhibit 06: Global hypothyroidism drug market 2016-2021 ($ millions) Exhibit 07: Symptoms of hyperthyroidism Exhibit 08: Treatment for hyperthyroidism Exhibit 09: Global hyperthyroidism drug market 2016-2021 ($ millions) Exhibit 10: Market scenario in Americas Exhibit 11: Thyroid gland disorder market in Americas 2016-2021 ($ millions) Exhibit 12: Market scenario in EMEA Exhibit 13: Thyroid gland disorder treatment market in EMEA 2016-2021 ($ millions) Exhibit 14: Market scenario in APAC Exhibit 15: Thyroid gland disorder treatment market in APAC 2016-2021 ($ millions) Exhibit 16: Impact of drivers Exhibit 17: Impact of drivers and challenges Exhibit 18: Competitive structure analysis of global thyroid gland disorder treatment market 2016 Exhibit 19: Competitive analysis of global thyroid gland disorder treatment market 2016 Exhibit 20: Market share analysis 2015 Exhibit 21: Market penetration of various vendors 2016 Exhibit 22: Abbott: Key highlights Exhibit 23: Abbott: Strength assessment Exhibit 24: Abbott: Strategy assessment Exhibit 25: Abbott: Opportunity assessment Exhibit 26: AbbVie: Key highlights Exhibit 27: AbbVie: Strength assessment Exhibit 28: AbbVie: Strategy assessment Exhibit 29: AbbVie: Opportunity assessment Exhibit 30: AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ million) Exhibit 31: Allergan: Key highlights Exhibit 32: Allergan: Strength assessment Exhibit 33: Allergan: Strategy assessment Exhibit 34: Allergan: Opportunity assessment Exhibit 35: Merck Sharp & Dohme: Key highlights Exhibit 36: Merck Sharp & Dohme: Strength assessment Exhibit 37: Merck Sharp & Dohme: Strategy assessment Exhibit 38: Merck Sharp & Dohme: Opportunity assessment Exhibit 39: Merck Sharp & Dohme: YoY revenue and growth rate of Euthyrox 2014-2015 ($ millions) Exhibit 40: Pfizer: Key highlights Exhibit 41: Pfizer: Strength assessment Exhibit 42: Pfizer: Strategy assessment Exhibit 43: Pfizer: Opportunity assessment Exhibit 44: RLC LABS: Strength assessment Exhibit 45: RLC LABS: Strategy assessment Exhibit 46: RLC LABS: Opportunity assessment

AbbVie, Pfizer, and Merck Sharp & Dohme